Logo
x

Search

Subscribe Now

Immunic

Immunic Reports P-IIb Study (CALDOSE-1) Results of IMU-838 (vidofludimus calcium) for Moderate-to-Severe Ulcerative Colitis

Immunic Reports P-IIb Study (CALDOSE-1) Results of IMU-838 (vidofludimus calcium) for Moderate-to-Severe Ulcerative Colitis

  • April 5, 2023
Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple Sclerosis

Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple...

  • November 18, 2022
Immunic Presents Preclinical Data of IMU-838 9 (vidofludimus calcium) in P-II (CALDOSE-1) Trial for the Treatment of Ulcerative Colitis at ECCO 2022

Immunic Presents Preclinical Data of IMU-838 9 (vidofludimus calcium) in P-II (CALDOSE-1) Trial for the Treatment of Ulcerative Co...

  • February 21, 2022
PharmaShots Weekly Snapshots (October 25 - 29, 2021)

PharmaShots Weekly Snapshots (October 25 - 29, 2021)

  • October 29, 2021
PharmaShots Weekly Snapshots (September 20 - 24, 2021)

PharmaShots Weekly Snapshots (September 20 - 24, 2021)

  • September 24, 2021
PharmaShots Weekly Snapshots (July 05 - 09, 2021)

PharmaShots Weekly Snapshots (July 05 - 09, 2021)

  • July 9, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.